• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The role of Helicobacter pylori in the pathogenesis of acid-peptic disease.

作者信息

Smoot D T, Scott V F

机构信息

Department of Medicine, Howard University College of Medicine, Washington, DC.

出版信息

J Assoc Acad Minor Phys. 1992;3(2):46-9.

PMID:1576460
Abstract

Helicobacter pylori (H pylori) is likely the most common cause of chronic active gastritis in humans. Also, H pylori has been found in up to 100% of patients with peptic ulcer disease. Recent studies have shown that long-term infection by H pylori is associated with an increased risk of developing gastric carcinoma. The mechanism(s), however, by which H pylori causes gastritis or leads to the development of peptic ulcers and gastric cancer is not well understood. The prevalence of H pylori gradually increases with age and is much higher in underdeveloped countries. In the United States, H pylori is present in 50% to 60% of people 60 years of age and older. The prevalence of H pylori in African Americans in the United States is approximately 38% higher than that in whites in all age groups. The route of transmission of this organism is unknown, but it is most likely from person to person. H pylori infection has been rather difficult to eradicate. At present, the most effective antimicrobial therapy includes bismuth salts and two antibiotics plus an H2-receptor antagonist.

摘要

相似文献

1
The role of Helicobacter pylori in the pathogenesis of acid-peptic disease.
J Assoc Acad Minor Phys. 1992;3(2):46-9.
2
Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.甲硝唑+四环素+枸橼酸铋钾与奥美拉唑+阿莫西林+枸橼酸铋钾治疗幽门螺杆菌相关性胃炎和消化性溃疡疾病的药理作用比较
Eur J Gastroenterol Hepatol. 1994 Dec;6 Suppl 1:S103-7.
3
First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy.黎巴嫩幽门螺杆菌的一线治疗:含铋四联疗法与 14 天序贯疗法的比较。
Microb Pathog. 2018 Apr;117:23-26. doi: 10.1016/j.micpath.2018.02.010. Epub 2018 Feb 8.
4
The case for treatment of dyspeptic patients infected with H. pylori.治疗幽门螺杆菌感染的消化不良患者的理由。
Eur J Surg Suppl. 1998(582):6-10. doi: 10.1080/11024159850191373.
5
CagA status and Helicobacter pylori eradication among dyspeptic patients.消化不良患者的细胞毒素相关基因A(CagA)状态与幽门螺杆菌根除情况
Gastroenterol Hepatol. 2005 Oct;28(8):441-4. doi: 10.1157/13078993.
6
[Helicobacter pylori in peptic ulcer and gastric cancer].[幽门螺杆菌与消化性溃疡和胃癌]
Gan To Kagaku Ryoho. 1995 Feb;22(2):169-78.
7
Helicobacter pylori: aggressor or innocent bystander?幽门螺杆菌:攻击者还是无辜旁观者?
Med Clin North Am. 1991 Jul;75(4):815-29. doi: 10.1016/s0025-7125(16)30413-8.
8
[Helicobacter pylori and ulcer disease: diagnosis and treatment 1995].[幽门螺杆菌与溃疡病:诊断与治疗,1995年]
Praxis (Bern 1994). 1996 Sep 24;85(39):1197-200.
9
[Therapy of Helicobacter pylori infection: current status].[幽门螺杆菌感染的治疗:现状]
Z Gastroenterol. 1993 Jul-Aug;31(7-8):459-63.
10
Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer.幽门螺杆菌在胃炎、消化性溃疡和胃癌发病机制中的作用。
Scand J Gastroenterol Suppl. 1993;196:3-6. doi: 10.3109/00365529309098333.